Careall Triple Antibiotic Plus Pain Relief

For topical use, healthcare providers generally recommend applying a small amount (approximately the size of a fingertip) to the affected area 1 to 3 times daily. The area may be covered with a sterile bandage if necessary. For ophthalmic (eye) use, the standard dose is usually a small ribbon of ointment applied to the affected eye every 3 to 4 hours, or as directed by an ophthalmologist.

In children, topical Bacitracin is used similarly to adults for minor skin injuries. For intramuscular use in infants (specifically for staphylococcal pneumonia), the dosage is strictly weight-based: infants under 2.5 kg typically receive 900 units/kg/24 hours in divided doses, while those over 2.5 kg may receive 1,000 units/kg/24 hours. This must only be performed in a hospital setting.

Renal Impairment

For systemic (IM) administration, Bacitracin is highly nephrotoxic (poisonous to kidneys). If used, extreme caution and frequent monitoring of renal function are required. No specific adjustments are needed for topical use unless applied to massive areas of broken skin.

Hepatic Impairment

No dosage adjustments are typically required for patients with liver disease, as the drug is primarily cleared by the kidneys.

Elderly Patients

Elderly patients may have age-related declines in kidney function. If systemic Bacitracin is used, healthcare providers will monitor creatinine clearance closely.

For topical ointment, clean the affected area before application. Do not use the ointment over large areas of the body or on deep puncture wounds, animal bites, or serious burns without consulting a doctor. For the eye ointment, avoid touching the tube tip to any surface, including the eye itself, to prevent contamination.

If you miss a dose, apply it as soon as you remember. If it is almost time for the next application, skip the missed dose and resume your regular schedule. Do not apply double the amount to catch up.

Topical overdose is unlikely to cause systemic toxicity. However, if the medication is swallowed, contact a poison control center immediately. Symptoms of systemic (IM) overdose include severe nephrotoxicity, evidenced by oliguria (reduced urine output) or azotemia (buildup of nitrogen waste).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

When used topically, Bacitracin is generally well-tolerated. The most common side effect is localized skin irritation, which may present as mild redness, itching, or a burning sensation at the site of application. These symptoms are usually transient and resolve once the medication is discontinued.

Allergic contact dermatitis (a skin rash caused by an immune response) occurs in a small percentage of patients. This may manifest as a persistent, itchy rash that spreads slightly beyond the area of application. If the rash worsens or does not improve, it may indicate a sensitization to the drug.

Systemic absorption from topical use is rare but can lead to more widespread hives (urticaria). In ophthalmic use, patients may experience temporary blurred vision or increased sensitivity to light immediately after application.

> Warning: Stop using Bacitracin and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction characterized by swelling of the face, tongue, or throat, difficulty breathing, and a rapid drop in blood pressure.
• Severe Skin Eruption: Generalized peeling or blistering (Stevens-Johnson Syndrome-like symptoms), though extremely rare with Bacitracin.
• Nephrotoxicity (Systemic only): Signs include blood in the urine, significant change in urine volume, or swelling in the legs and feet.

Prolonged use of Bacitracin may result in overgrowth of non-susceptible organisms, including fungi. This is known as a superinfection. If the infection does not clear within 7 to 10 days, or if new symptoms appear, a healthcare provider should re-evaluate the treatment plan.

Parenteral (Injection) Use Only: Bacitracin for injection carries an FDA Black Box Warning regarding nephrotoxicity. The drug can cause renal failure due to tubular and glomerular necrosis. Renal function must be monitored daily during systemic therapy. Fluid intake should be maintained at high levels to reduce the concentration of the drug in the renal tubules.

Report any unusual symptoms to your healthcare provider.

Bacitracin should only be used for the purpose it was prescribed. Topical formulations are for external use only and should never be ingested or used in the eyes (unless it is the specific ophthalmic formulation).

Nephrotoxicity Warning: According to the FDA-approved label for Bacitracin for injection, its use is associated with significant kidney damage. This is particularly dangerous for infants and patients with pre-existing renal impairment. Daily urinalysis and blood chemistry (BUN and Creatinine) are mandatory during systemic treatment.

• Allergic Reactions: There is a risk of cross-sensitivity with other polypeptide antibiotics. If you have had a reaction to neomycin or polymyxin B, discuss this with your doctor.
• Superinfection: As with all antibiotics, long-term use can lead to the growth of resistant bacteria or fungi (e.g., Candida).
• Deep Wounds: Bacitracin is not intended for deep puncture wounds, animal bites, or serious burns without medical supervision, as systemic absorption risk increases.

For topical use, no specific lab monitoring is required. For systemic (IM) use, healthcare providers will monitor:

• Renal Function: Daily BUN (Blood Urea Nitrogen) and serum creatinine.
• Fluid Balance: Strict monitoring of intake and output (I&O).
• Urinalysis: Checking for casts or protein in the urine.

Topical Bacitracin does not typically affect the ability to drive. Ophthalmic Bacitracin may cause temporary blurred vision; patients should wait until their vision clears before operating heavy machinery.

There are no known direct interactions between topical Bacitracin and alcohol. However, alcohol can impair wound healing and immune function.

For minor skin infections, treatment is usually stopped once the wound has healed. If a rash or signs of allergy develop, the medication should be discontinued immediately.

> Important: Discuss all your medical conditions with your healthcare provider before starting Bacitracin.

When Bacitracin is administered systemically (IM), it must never be used with other nephrotoxic (kidney-damaging) drugs. This includes Aminoglycosides (such as streptomycin, neomycin, or kanamycin). The combination significantly increases the risk of permanent kidney failure and neuromuscular blockade (respiratory paralysis).

• Neuromuscular Blocking Agents: Systemic Bacitracin can enhance the effects of muscle relaxants used during surgery (like succinylcholine), potentially leading to prolonged respiratory depression.
• Other Polypeptide Antibiotics: Using systemic Bacitracin with Polymyxin B may increase the risk of neurotoxicity and nephrotoxicity.

• Topical Steroids: While often used together in combination products, using a topical steroid over a large area with Bacitracin might mask signs of a worsening infection or an allergic reaction to the antibiotic.

There are no known food interactions with topical or ophthalmic Bacitracin. For systemic use, maintaining adequate hydration is the primary nutritional concern to protect the kidneys.

No specific herbal interactions have been clinically documented for topical Bacitracin. However, patients using supplements that affect kidney function (such as high-dose creatine) should inform their doctor if systemic Bacitracin is being considered.

Bacitracin does not typically interfere with standard blood or urine laboratory tests, though it may interfere with certain microbiological assays used to identify other bacteria.

For each major interaction, explain:

• Mechanism: Systemic interactions primarily involve additive toxicities (nephrotoxicity) or pharmacodynamic enhancement of neuromuscular block.
• Clinical Consequence: Increased risk of kidney failure or breathing difficulties.
• Management: Avoid co-administration of nephrotoxic agents and monitor renal labs daily.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Hypersensitivity: Bacitracin is strictly contraindicated in individuals with a history of previous hypersensitivity or severe allergic reactions to the drug or any component of the formulation.
• Severe Renal Impairment (for IM use): Because the drug is highly nephrotoxic, it should not be used systemically in patients with existing kidney failure unless the benefits clearly outweigh the life-threatening risks.

• Large Open Wounds: Use with caution on extensive areas of broken skin due to the risk of systemic absorption and subsequent toxicity.
• Pregnancy: Use only if clearly needed, as systemic safety data is limited.

Patients allergic to other polypeptide antibiotics (like Polymyxin B) may occasionally show cross-reactivity to Bacitracin. If you have a known 'triple antibiotic' allergy, you should avoid all components until tested by an allergist.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Bacitracin.

Bacitracin is classified as FDA Pregnancy Category C. This means animal reproduction studies have not been conducted, and it is not known whether Bacitracin can cause fetal harm when administered to a pregnant woman. Topical use is generally considered low-risk due to minimal absorption, but it should only be used if the potential benefit justifies the potential risk to the fetus.

It is not known whether Bacitracin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Bacitracin is administered to a nursing woman. For topical use, ensure the medication is not applied to the breast area where the infant might ingest it.

Topical Bacitracin is widely used and generally safe in children for minor injuries. The systemic (IM) use is specifically indicated for infants with staphylococcal pneumonia and empyema, but it requires intensive hospital monitoring due to the high risk of renal toxicity in neonates.

Clinical studies of Bacitracin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, because elderly patients are more likely to have decreased renal function, care should be taken in dose selection for systemic use, and renal function should be monitored.

In patients with impaired renal function, systemic Bacitracin can accumulate rapidly, leading to toxic levels. GFR-based monitoring is essential. Topical use remains safe for most patients with renal disease as long as the skin barrier is relatively intact.

No specific adjustments are documented for hepatic impairment, as Bacitracin is not primarily metabolized by the liver.

> Important: Special populations require individualized medical assessment.

Bacitracin is a polypeptide antibiotic that inhibits bacterial cell wall synthesis. It specifically targets the cycle of the C55-isoprenyl pyrophosphate (also known as bactoprenol) carrier molecule. By binding to this lipid carrier, Bacitracin prevents the enzymatic dephosphorylation required to regenerate the carrier for subsequent rounds of peptidoglycan transport. This halts the assembly of the bacterial cell wall, leading to cell death.

Bacitracin is primarily bactericidal against Gram-positive bacteria. Its effect is concentration-dependent at the site of infection. For topical application, it provides high local concentrations that far exceed the Minimum Inhibitory Concentration (MIC) for most Staphylococcus and Streptococcus species.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Topical); 100% (IM) |

| Protein Binding | Minimal |

| Half-life | Not well-defined for topical; 1.5–2 hours (Systemic) |

| Tmax | 1–2 hours (after IM injection) |

| Metabolism | None significant |

| Excretion | Renal (10%–40% unchanged) |

Bacitracin is a mixture of related cyclic polypeptides. The main component is Bacitracin A. Its molecular formula is C66H103N17O16S, with a molecular weight of approximately 1422.69 g/mol. It is soluble in water and alcohol but unstable in alkaline solutions.

Bacitracin is classified as a Polypeptide Antibiotic. It is distinct from aminoglycosides, macrolides, and beta-lactams. Related medications include Polymyxin B and Colistin, though their mechanisms and spectra of activity differ.